Logo Logo
Help
Contact
Switch Language to German

Tokarew, Nicholas J.A.; Gosálvez, Javier Suárez; Nottebrock, Alessia; Briukhovestka, Daria; Endres, Stefan ORCID logoORCID: https://orcid.org/0000-0002-4703-537X; Cadilha, Bruno L. und Kobold, Sebastian ORCID logoORCID: https://orcid.org/0000-0002-5612-4673 (2022): Flow cytometry detection and quantification of CAR T cells into solid tumors. In: Methods in Cell Biology, Vol. 167: pp. 99-122

Full text not available from 'Open Access LMU'.

Abstract

Adoptive T cell therapy (ACT) is a therapeutic approach which employs genetically manipulated autologous T cells to target and eliminate a patient's malignancy. This novel therapeutic approach, when employing a chimeric antigen receptor (CAR) targeting CD19-expressing B cells, has shown remarkable success in treating acute B-cell lymphocytic leukemia. However, blood born malignancies represent only a fraction of cancers which affect patients. Unfortunately, the utilization of ACT to target solid malignancies has only shown marginal success rates. There are many known obstacles which hinder CAR T cell therapy in patients suffering from solid cancer, one notable obstacle is the effective trafficking of CAR T cells to the tumor site. With the rapid advancement of novel approaches and targets which may enhance CAR T cell infiltration into solid tumors, a standardized approach to assess and measure CAR T cell infiltration becomes imperative in order to compare these different approaches across platforms. Here we describe a flow cytometry method which enables the rapid detection and quantification of CAR T cells which have reached and entered the tumor mass following intravenous injection. Competence with single cell preparation and flow cytometry is required for optimal results.

Actions (login required)

View Item View Item